Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
US Judge Seeks Explanation for DOJ’s Decision to Drop Gautam Adani Bribery Case 
Trip.com Shares Tumble After Q1 Profit Drops and Weak Revenue Growth Outlook 
OpenAI May Delay IPO to 2027 Amid $1 Trillion Valuation Goal 
SK Hynix Moves Closer to New York ADR Listing Amid AI Chip Boom 
OpenAI IPO Delay Weighs on SoftBank Shares as AI Valuation Concerns Grow 
China Eastern Orders 25 Airbus A330neo Jets in $9.35 Billion Deal to Boost International Expansion 
SpaceX Stock Rebounds After Sharp Selloff, But Valuation Concerns Persist 
SpaceX, Charter Communications Explore Mobile Partnership to Expand Starlink Wireless Service 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Apple Supplier Stocks Slide as Samsung, SK Hynix Lead Selloff After Apple Price Hikes 
Fortescue Faces Class Action Over Sexual Harassment Claims at Australian Mining Sites 
DALLAS and FORT WORTH, Texas, Feb. 28, 2017 -- Neos Therapeutics, Inc. (NASDAQ:NEOS), a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release (XR) products using its proprietary modified-release drug delivery and orally disintegrating tablet (ODT) technology platforms, today announced that Vipin Garg, Ph.D., president and chief executive officer, will present a company overview at the upcoming Cowen and Company 37th Annual Health Care Conference on Tuesday, March 7, 2017 at 8:00 a.m. ET in Boston, MA.
A live webcast of the presentation will be available on the Investor Relations page of the company’s website at http://investors.neostx.com/.
About Neos Therapeutics
Neos Therapeutics, Inc. is a pharmaceutical company focused on developing, manufacturing and commercializing products utilizing its proprietary modified-release drug delivery technology platforms. Adzenys XR-ODTTM, indicated for the treatment of ADHD in patients 6 years of age and older, is the first approved product using the Company’s extended-release (XR)-orally disintegrating tablet (ODT) technology platform. Neos, which is initially focusing on the treatment of ADHD, has filed New Drug Applications with the U.S. Food and Drug Administration for two other branded product candidates that are XR medications in ODT or oral suspension dosage forms. In addition, Neos manufactures and markets its generic equivalent of the branded product Tussionex®, an XR oral suspension of hydrocodone and chlorpheniramine indicated for the relief of cough and upper respiratory symptoms of a cold.1
1Tussionex® is a registered trademark of the UCB Group of Companies.
Contacts: Richard Eisenstadt Chief Financial Officer Neos Therapeutics (972) 408-1389 [email protected] Sarah McCabe Vice President Stern Investor Relations, Inc. (212) 362-1200 [email protected]
